Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-15
2010-02-02
Wang, Shengjun (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S373000, C514S461000, C514S469000, C514S472000, C514S601000, C514S602000, C514S709000, C514S923000, C424S449000
Reexamination Certificate
active
07655681
ABSTRACT:
A method of treating or preventing Obstructive Sleep Apnea (OSA) comprises the administration of a pharmacologically effective amount of zonisamide to a patient in need thereof, with the proviso that OSA caused by external mechanical obstruction of the airways, such as by mucus, is excluded. Also disclosed is the use of zonisamide for the manufacture of a medicament useful in the treatment; a protective patch comprising zonisamide and a pharmaceutically acceptable carrier for transdermal or transmucosal administration to a person suffering from OSA; and the use of zonisamide for the manufacture of a diagnostic device, kit or composition for the diagnosis of sleep disordered breathing.
REFERENCES:
patent: 6489350 (2002-12-01), Benedyk
patent: WO-0162243 (2001-08-01), None
LaRoche et al, “The New Antiepileptic Drugs”, JAMA, 291 (5), Feb. 4, 2204, p. 605-614.
Yoshiaki Saito, et al., “A Case of Alternating Hemiplegia of Childhood With Cerebellar Atrophy,” Pediatric Neurology, vol. 19, No. 1, 1998.
Spiller HA, Dunaway MD, Cutino L. “Massive gabapentin and presumptive quetiapine overdose.”Vet Hum Toxicol. Aug. 2002. p. 243-4. 44(4).
Berry RB, Kouchi K, Bower J, Prosise G, Light RW. “Triazolam in patients with obstructive sleep apnea.”Am. J. Respir. Crit. Care Med., Feb. 1995, p. 450-454, vol. 151, No. 2.
Schuld A, Kraus T, Haack M, Hinze-Selch D, Pollmächer T. “Obstructive sleep apnea syndrome induced by clonazepam in a narcoleptic patient with REM-sleep-behavior disorder.”J Sleep Res. Dec. 1999. p. 321-2. 8(4).
Hedner J, Hedner T, Jonason J, Lundberg D. “GABA-ergic mechanisms in central respiratory control in the anesthetized rat.”Naunyn Schmiedebergs Arch Pharmacol. 1981. p. 315-20. 317(4).
Lambert MV, Bird JM. “Obstructive sleep apnoea following rapid weight gain secondary to treatment with vigabatrin (Sabril).”Seizure. Jun. 1997. p. 233-5. 6(3).
Saletu A, Parapatics S, Saletu B, Anderer P, Prause W, Putz H, Adelbauer J, Saletu-Zyhlarz GM. “On the pharmacotherapy of sleep bruxism: placebo-controlled polysomnographic and psychometric studies with clonazepam.”Neuropsychobiology. May 23, 2005. p. 214-25. 51(4).
Stremski ES, Brady WB, Prasad K, Hennes HA. “Pediatric carbamazepine intoxication.”Ann Emerg Med. May 1995. p. 624-30. 25(5).
Grote Ludger
Hedner Jan
Stenlof Kaj
Dickstein & Shapiro LLP
Grote Ludger
Hedner Jan
Javanmard Sahar
Stenlof Kaj
LandOfFree
Method of treating and diagnosing sleep disordered breathing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating and diagnosing sleep disordered breathing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating and diagnosing sleep disordered breathing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4163437